Jun. 28 at 5:35 PM
$RIGL I view our IRAK1/4 program as a potential platform - where the first proof-of-concept happens to be in lower-risk MDS. Then we can potentially expand outward to higher-risk MDS, AML, combinations, etc. And we know large pharma is looking for high-quality immunology assets for blockbuster indications. R289 blocks Toll-like Receptors and IL-1 receptors so has the potential to treat patients who do not respond to traditional TNF-blockers (like Humira). This program is potentially massive.
I know these boards are for speculation, but I am a long-term investor and tend to accumulate for years (if possible). The next key event for me is ASH. Earnings too but I want to see the R289 data. I have no price target but am extremely bullish.
